
A research team shows how signaling by an immune system component called interleukin-6 (IL-6) appears to play an important role in driving aggressive, therapy-resistant prostate cancer.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/EQ8N9DOqlyo/150604162605.htm